1. Home
  2. SSM vs BIVI Comparison

SSM vs BIVI Comparison

Compare SSM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSM

Sono Group N.V. Ordinary Shares

HOLD

Current Price

$3.93

Market Cap

10.6M

Sector

N/A

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.50

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSM
BIVI
Founded
2016
2013
Country
Germany
United States
Employees
43
13
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
11.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SSM
BIVI
Price
$3.93
$1.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
93.9K
84.6K
Earning Date
05-20-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1,462,987.20
N/A
Revenue Next Year
$48.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.42
$0.88
52 Week High
$10.54
$9.09

Technical Indicators

Market Signals
Indicator
SSM
BIVI
Relative Strength Index (RSI) 33.47 55.08
Support Level $3.42 $1.45
Resistance Level $7.60 $1.71
Average True Range (ATR) 0.85 0.11
MACD -0.05 -0.00
Stochastic Oscillator 8.55 52.08

Price Performance

Historical Comparison
SSM
BIVI

About SSM Sono Group N.V. Ordinary Shares

Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: